Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

In patients with newly diagnosed O3<sup>IDHmt/Codel</sup> from the POLA cohort, first-line PCV/RT was associated with better OS outcomes compared with TMZ/RT. Our data suggest that the improved safety profile associated with TMZ comes at the cost of inferior efficacy in this population. Further investigation using prospective randomized studies is warranted.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-10-02
DOI
https://doi.org/10.1200/jco.24.00049
Citations
25
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
10.95
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

Pierre‐Yves Boëlle, Clovis Adam, Dominique Figarella‐Branger, M. Abad et al.
25 citations
Journal of Clinical Oncology
Glioma Diagnosis and Treatment
10.95
article

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

Pierre‐Yves Boëlle, Clovis Adam, Dominique Figarella‐Branger, M. Abad, Mathilde Ducloie, Veronique Bourg, Caroline Dehais, Audrey Rousseau, F Vandenbos-Burel, François Labrousse, Damien Ricard, Claude‐Alain Maurage, David Meyronet, Catherine Godfraind, Khê Hoang‐Xuan, Stefania Cuzzubbo, Ilyess Zemmoura, Pascal Roger, Luc Bauchet, Charlotte Bronnimann, Benoît Lhermitte, Saioa López, Philippe Meneï, Luc Taillandier, Bertrand Mathon, T Khallil, Élodie Vauléon, Marie Andraud, Romain Appay, Thierry Faillot, Salah Eddine Oussama Kacimi, Michel Wager, Christophe Joubert, Elisabeth Cohen-Moyal, Franck Bielle, Isabelle Quintin‐Roué, Elizabeth Cohen‐Jonathan Moyal, Romuald Seizeur, François Ghiringhelli, H. Adle-Biassette, Apolline Djelad, François Ducray, Agustí Alentorn, Valérie Rigau, Émeline Tabouret, Guillaume Chotard, Cécilia Rousselot‐Denis, G. Gauchotte, J. Bryan Iorgulescu, Dominique Cazals‐Hatem, Mehdi Touat, H Aubriot-Lorton, Mario Campone, C. Gaultier, Marc Sanson, Serge Milin, Lucia Nichelli, Emmanuelle Uro‐Coste, Olivier Chinot, C. Desenclos, Alain Carpentier, Philippe Colin, Fabien Forest, Ioana Carpiuc, M J Motso-Fotso, T Cruel, Noor Hamdan, F. Dhermain, Karim Labrèche, G. Noël, N Guillain, Ahmed Idbaïh, Olivier Langlois, Philippe Richard, Alice Thomas, L. Feuvret, Carole Ramirez, Delphine Loussouarn, Danchristian Chiforeanu, Florent Marguet, M.D. Diebold, Claire Bléchet, E.-M. Gueye, Nadia Younan, Michèle Bernier, M.-C. Tortel, Fabrice Parker, Suzanne Tran, Jean Sébastien Guillamo
article en
25 citations

Abstract

In patients with newly diagnosed O3<sup>IDHmt/Codel</sup> from the POLA cohort, first-line PCV/RT was associated with better OS outcomes compared with TMZ/RT. Our data suggest that the improved safety profile associated with TMZ comes at the cost of inferior efficacy in this population. Further investigation using prospective randomized studies is warranted.

Journal of Clinical OncologyVol. 43(3)
Université Claude Bernard Lyon 1 (FR), Brigham and Women's Hospital (US), Centre National de la Recherche Scientifique (FR), The University of Texas MD Anderson Cancer Center (US), Université Toulouse III - Paul Sabatier (FR), Université de Bordeaux (FR), Inserm (FR), Université Paris Cité (FR), Aix-Marseille Université (FR), Hôpital Beaujon (FR), Institut Gustave Roussy (FR), Centre Hospitalier Universitaire de Nice (FR), Service de Santé des Armées (FR), Sorbonne Université (FR), Centre de Recherches en Cancérologie de Toulouse (FR), Institut de Cancérologie Strasbourg (FR), Lille’s Cardiology Hospital (FR), Oncogenesis Stress Signaling (FR), Centre Georges François Leclerc (FR), Assistance Publique – Hôpitaux de Paris (FR), Centre Hospitalier Régional et Universitaire de Nancy (FR), Hospices Civils de Lyon (FR), Institut de Cancérologie de l'Ouest (FR), Centre Eugène Marquis (FR), Institute Cancer De La Loire Lucien Neuwirth (FR), Centre Hospitalier Universitaire d'Angers (FR), Centre Hospitalier Universitaire de Caen Normandie (FR), Hôpital Nord (FR), Hôpitaux Universitaires Paris-Ouest (FR), Centre de Recherche en Cancérologie de Lyon (FR), Institut Claudius Regaud (FR), Hôpital d'instruction des Armées Percy (FR), Institut du Cerveau (FR), Hôpital Foch (FR), Production et analyse de données en sciences de la vie et en santé (FR), Université de Rennes (FR), Université de Rouen Normandie (FR), Université de Caen Normandie (FR)
Good health and well-being
Openalex Percentile: Top 1%
Glioma Diagnosis and Treatment
10.95
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.